Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.56 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14366589 | 0.95 | PARP1 (0.55) | PARP1SHMT2TSHRKMT2ACYP2D6 | |
| Hydrochloric Acid SCHEMBL5583229 | 0.94 | PARP1 (0.54) | PARP1SHMT2TSHRKMT2ACYP2D6 | |
| SCHEMBL6071696 | 0.93 | SHMT2 (0.54) | PARP1SHMT2TSHRKMT2ACYP2D6 | |
| SCHEMBL14366588 | 0.90 | PARP1 (0.58) | PARP1SHMT2KMT2ACYP2D6 | |
| Hydrochloric Acid SCHEMBL5583244 | 0.89 | PARP1 (0.57) | PARP1SHMT2KMT2ACYP2D6 | |
| SCHEMBL6071241 | 0.84 | MAPT (0.55) | PARP1TSHRKMT2AKDM4EALDH1A1 | |
| SCHEMBL6070900 | 0.84 | MAPK10 (0.58) | PARP1TSHRKMT2AKDM4EALDH1A1 | |
| SCHEMBL6070940 | 0.82 | MAPK10 (0.56) | PARP1TSHRKMT2AKDM4EALDH1A1 | |
| SCHEMBL6071369 | 0.82 | MAPK10 (0.60) | PARP1TSHRKMT2AKDM4EALDH1A1 | |
| SCHEMBL14366582 | 0.82 | PARP1 (0.58) | PARP1KMT2ATLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | claimed |
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K1, MAP3K19, MAP3K20 | PARP1 840/4885SHMT2 1517/4885TSHR 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.